Do analysts recommend IZTC or CNTB?

Connect Biopharma has a consensus price target of $7.29, indicating a potential upside of 240.45%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has stronger earnings and valuation, IZTC or CNTB?

Invizyne Technologies has higher earnings, but lower revenue than Connect Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Connect Biopharma $233K 578.30 -$55.48M -$1.15 N/A

Is IZTC or CNTB more profitable?

Invizyne Technologies' return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Connect Biopharma N/A -122.29% -97.07%

Do analysts rate PYXS or IZTC?

Pyxis Oncology presently has a consensus price target of $6.86, indicating a potential upside of 162.73%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, PYXS or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Pyxis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pyxis Oncology $13.86M 11.93 -$79.62M -$1.31 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is PYXS or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Invizyne Technologies N/A N/A N/A

Do analysts rate HUMA or IZTC?

Humacyte currently has a consensus target price of $6.25, indicating a potential upside of 900.32%. Given Humacyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Humacyte is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, HUMA or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Humacyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.02M 68.81 -$40.83M -$0.57 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Which has stronger valuation & earnings, MIST or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Milestone Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Milestone Pharmaceuticals $1.78M 80.95 -$63.06M -$0.68 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is MIST or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Invizyne Technologies N/A N/A N/A

Do analysts prefer IZTC or UNCY?

Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 302.78%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Unicycive Therapeutics 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has stronger earnings & valuation, IZTC or UNCY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Unicycive Therapeutics N/A N/A -$26.56M -$2.21 N/A

Is IZTC or UNCY more profitable?

Invizyne Technologies' return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Unicycive Therapeutics N/A -134.69% -84.51%

Invizyne Technologies (IZTC) Competitors

$4.71 +0.01 (+0.21%)

As of 07/24/2026

Compare

IZTC vs. CNTB, PYXS, HUMA, MIST, and UNCY

Should you buy Invizyne Technologies stock or one of its competitors? MarketBeat compares Invizyne Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invizyne Technologies include Connect Biopharma (CNTB), Pyxis Oncology (PYXS), Humacyte (HUMA), Milestone Pharmaceuticals (MIST), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry.

How does Invizyne Technologies compare to Connect Biopharma?

Invizyne Technologies (NASDAQ:IZTC) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Connect Biopharma has a consensus price target of $7.29, indicating a potential upside of 240.45%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Connect Biopharma had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Connect Biopharma and 0 mentions for Invizyne Technologies. Connect Biopharma's average media sentiment score of 1.73 beat Invizyne Technologies' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Connect Biopharma	Very Positive

Invizyne Technologies has higher earnings, but lower revenue than Connect Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Connect Biopharma	$233K	578.30	-$55.48M	-$1.15	N/A

Invizyne Technologies' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

Connect Biopharma beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Invizyne Technologies' return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Invizyne Technologies	N/A	N/A	N/A

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pyxis Oncology had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Pyxis Oncology and 0 mentions for Invizyne Technologies. Pyxis Oncology's average media sentiment score of 0.80 beat Invizyne Technologies' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Positive
Invizyne Technologies	Neutral

Invizyne Technologies has lower revenue, but higher earnings than Pyxis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	11.93	-$79.62M	-$1.31	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Pyxis Oncology presently has a consensus price target of $6.86, indicating a potential upside of 162.73%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Pyxis Oncology beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Humacyte currently has a consensus target price of $6.25, indicating a potential upside of 900.32%. Given Humacyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Humacyte is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Humacyte had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Humacyte and 0 mentions for Invizyne Technologies. Humacyte's average media sentiment score of 0.48 beat Invizyne Technologies' score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Neutral
Invizyne Technologies	Neutral

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Invizyne Technologies has lower revenue, but higher earnings than Humacyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.02M	68.81	-$40.83M	-$0.57	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Invizyne Technologies' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Invizyne Technologies	N/A	N/A	N/A

Summary

Humacyte beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

How does Invizyne Technologies compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Invizyne Technologies has lower revenue, but higher earnings than Milestone Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.78M	80.95	-$63.06M	-$0.68	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Milestone Pharmaceuticals and 0 mentions for Invizyne Technologies. Milestone Pharmaceuticals' average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Very Positive
Invizyne Technologies	Neutral

Milestone Pharmaceuticals presently has a consensus target price of $7.25, suggesting a potential upside of 525.00%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Invizyne Technologies' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Invizyne Technologies	N/A	N/A	N/A

Summary

Milestone Pharmaceuticals beats Invizyne Technologies on 9 of the 11 factors compared between the two stocks.

How does Invizyne Technologies compare to Unicycive Therapeutics?

Invizyne Technologies (NASDAQ:IZTC) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$2.21	N/A

Invizyne Technologies' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Unicycive Therapeutics	N/A	-134.69%	-84.51%

In the previous week, Unicycive Therapeutics had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 0 mentions for Invizyne Technologies. Unicycive Therapeutics' average media sentiment score of 0.56 beat Invizyne Technologies' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Unicycive Therapeutics	Positive

40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 302.78%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Unicycive Therapeutics beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IZTC vs. The Competition

Export

Metric	Invizyne Technologies	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$103.16M	$357.18M	$6.87B	$12.26B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	N/A	N/A	27.14	23.64
Price / Sales	N/A	228.84	517.08	89.50
Price / Cash	N/A	22.44	50.54	59.64
Price / Book	N/A	4.88	10.28	6.07
Net Income	N/A	-$141.03M	$3.60B	$331.99M
7 Day Performance	-21.76%	-1.69%	-1.27%	-0.63%
1 Month Performance	-34.03%	0.21%	-0.37%	-2.00%
1 Year Performance	-52.66%	39.82%	18.30%	13.62%

Invizyne Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IZTC Invizyne Technologies	N/A	$4.71 +0.2%	N/A	-49.2%	$103.16M	N/A	N/A	29	Gap Up
CNTB Connect Biopharma	4.571 of 5 stars	$2.38 +1.7%	$7.29 +206.1%	-8.9%	$149.85M	$233K	N/A	110	News Coverage Positive News
PYXS Pyxis Oncology	2.9929 of 5 stars	$2.36 +5.8%	$6.86 +190.6%	+94.8%	$149.52M	$13.86M	N/A	60
HUMA Humacyte	3.4167 of 5 stars	$0.66 +0.8%	$6.25 +840.3%	-76.6%	$147.58M	$2.02M	N/A	150
MIST Milestone Pharmaceuticals	2.2419 of 5 stars	$1.19 -4.4%	$7.25 +511.8%	-26.1%	$147.53M	$1.78M	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invizyne Technologies (IZTC) Competitors

IZTC vs. CNTB, PYXS, HUMA, MIST, and UNCY

How does Invizyne Technologies compare to Connect Biopharma?

Summary

How does Invizyne Technologies compare to Pyxis Oncology?

Summary

How does Invizyne Technologies compare to Humacyte?

Summary

How does Invizyne Technologies compare to Milestone Pharmaceuticals?

Summary

How does Invizyne Technologies compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invizyne Technologies (IZTC) Competitors

IZTC vs. CNTB, PYXS, HUMA, MIST, and UNCY

How does Invizyne Technologies compare to Connect Biopharma?

Do institutionals & insiders believe in IZTC or CNTB?

Do analysts recommend IZTC or CNTB?

Does the media prefer IZTC or CNTB?

Which has stronger earnings and valuation, IZTC or CNTB?

Is IZTC or CNTB more profitable?

Summary

How does Invizyne Technologies compare to Pyxis Oncology?

Is PYXS or IZTC more profitable?

Do insiders and institutionals have more ownership in PYXS or IZTC?

Does the media prefer PYXS or IZTC?

Which has stronger earnings and valuation, PYXS or IZTC?

Do analysts rate PYXS or IZTC?

Summary

How does Invizyne Technologies compare to Humacyte?

Do analysts rate HUMA or IZTC?

Does the media prefer HUMA or IZTC?

Do institutionals & insiders have more ownership in HUMA or IZTC?

Which has better earnings & valuation, HUMA or IZTC?

Is HUMA or IZTC more profitable?

Summary

How does Invizyne Technologies compare to Milestone Pharmaceuticals?

Which has stronger valuation & earnings, MIST or IZTC?

Does the media prefer MIST or IZTC?

Do analysts rate MIST or IZTC?

Do insiders & institutionals hold more shares of MIST or IZTC?

Is MIST or IZTC more profitable?

Summary

How does Invizyne Technologies compare to Unicycive Therapeutics?

Which has stronger earnings & valuation, IZTC or UNCY?

Is IZTC or UNCY more profitable?

Does the media refer more to IZTC or UNCY?

Do insiders and institutionals have more ownership in IZTC or UNCY?

Do analysts prefer IZTC or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools